1. NeuroStar Prescribing Information.
  2. Kessler RC, et al. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 62(6):593-602.
  3. Data on file. Neuronetics, Inc.
  4. American Psychiatric Association (2010). (eds: Gelenberg, AJ, Freeman, MP, Markowitz, JC, Rosenbaum, JF, Thase, ME, Trivedi, MH, Van Rhoads, RS). Practice Guidelines for the Treatment of Patients with Major Depressive Disorder, 3rd Edition.
  5. Avery, et al. (2008). Transcranial Magnetic Stimulationin the Acute Treatment of Major Depressive Disorder: Clinical Response in an Open-Label Extension Trial. J Clin Psychiatry,, 69 (3): 441-451.
  6. Carpenter LL, et al. (2012). Transcranial Magnetic Stimulation (TMS) for Major Depression: A Multisite Naturalistic, Observational Study of Acute Treatment Outcomes in Clinical Practice. Depress Anxiety, 29(7):587-596.
  7. O’Reardon JP, et al. (2007). Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial. Biol Psychiatry, 62(11):1208-1216.
  8. George MS, et al. (2010). Daily Left Prefrontal Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder: A Sham-Controlled Randomized Trial. Arch Gen Psychiatry, 67(5):507-516.
  9. McDonald WM, et al. (2011). Improving the Antidepressant Efficacy of Transcranial Magnetic Stimulation: Maximizing the Number of Stimulations and Treatment Locations in Treatment-Resistant Depression. Depression Anxiety, 28:973-980.
  10. Janicak PG, et al. (2010). Durability of Clinical Benefit with Transcranial Magnetic Stimulation (TMS) in the Treatment of Pharmacoresistant Major Depression: Assessment of Relapse During a 6-Month, Multisite, Open-Label Study. Brain Stimulation, 3(4):187-199.
  11. Janicak PG, et al. (2008). Transcranial Magnetic Stimulation in the Treatment of Major Depressive Disorder: A Comprehensive Summary of Safety Experience from Acute Exposure, Extended Exposure, and During Reintroduction Treatment. J Clin Psychiatry, 69(2):222-232.
  12. Liston C, et al. (2014) Default Mode Network Mechanisms of Transcranial Magnetic Stimulation in Depression. Biol. Psychiatry 76(7): 517–526.
  13. Trivedi MH, et al. (2006). Evaluation of Outcomes with Citalopram for Depression Using Measurement-Based Care in STAR*D Implications for Clinical Practice. Am J Psychiatry, 163(1):28-40.
  14. Rush AJ, et al. (2006). Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. Am J Psychiatry, 163:1905–1917.
  15. Fava M, et al. (2006). A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A Star*D Report. Am J Psychiatry, 163(7):1161-1172.
  16. McGrath PJ, et al. (2006). Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report. Am J Psychiatry, 163(9):1531-1541.
  17. 2013 CPT Current Procedural Terminology Professional Edition, American Medical Association.
  18. Regulation No.: CMS-1656-FC Federal Register / Vol. 81, No. 219 / Monday, November 14, 2016 / Rules and Regulations
  19. Mantovani A, et al. (2012). Long-Term Efficacy of Repeated Daily Prefrontal Transcranial Magnetic Stimulation (TMS) in Treatment-Resistant Depression. Depression Anxiety, 29 (10): 883-890.
  20. Dunner DL, et al. (2014) A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation (TMS) for Patients with Pharmacoresistant Major Depression: Durability of Benefit Over a One-Year Follow-Up Period. J Clin Psych, 75(12):1394-1401.